Doctor Amit Khera
Verve Therapeutics, Boston (United States of America)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models
Event: ESC Congress 2023
Topic: Drug therapy
Session: What's new in lipid lowering?
An in vivo CRISPR base editing therapy to inactivate the ANGPTL3 gene: nomination of a development candidate for VERVE-201
Event: ESC Congress 2022
Topic: Gene Therapy, Cell Therapy
Session: RNA and gene therapy of vascular diseases
ESC 365 is supported by
